FNY Partners Fund’s Crescent Biopharma CBIO Stock Holding History

FNY Partners Fund’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-15	Closed	-$16K	–	627
2017 Q2	$16K	Buy	+15	New	+$12.4K	﹤0.01%	359

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FNY Partners Fund's CBIO Position: Q3 2017 in Review

FNY Partners Fund sold out of Crescent Biopharma (CBIO) in Q3 2017, closing a stake of 15 shares — an estimated $16K sold.

FNY Partners Fund first reported a position in CBIO in Q2 2017 and held it in 1 quarter. The position peaked at $16K in Q2 2017. 58 funds tracked by Wall St. Rank hold CBIO as of Q3 2017.

FNY Partners Fund reported no remaining Crescent Biopharma position as of Q3 2017 after selling out during the quarter.
FNY Partners Fund sold 15 Crescent Biopharma shares in Q3 2017, an estimated $16K.
FNY Partners Fund first reported a position in Crescent Biopharma in Q2 2017 and held it in 1 quarter.
FNY Partners Fund's Crescent Biopharma position peaked at $16K in Q2 2017.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.